Found: 1
Select item for more details and to access through your institution.
Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 1, p. 313, doi. 10.1007/s13300-020-00968-x
- By:
- Publication type:
- Article